Vanderbilt Epidemiology Center, Institute of Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN.
Division of Cardiovascular Health and Disease.
Blood Adv. 2018 Nov 27;2(22):3088-3096. doi: 10.1182/bloodadvances.2017013359.
Abdominal aortic aneurysm (AAA) is associated with high morbidity and mortality and is an established cause of unbalanced hemostasis. A number of hemostatic biomarkers have been associated with AAA; however, the utility of hemostatic biomarkers in AAA diagnosis and prognosis is unclear. The aim of the present study was to characterize the potential prognostic value of D-dimer and markers of altered hemostasis in a large cohort of patients with AAAs characterized by either fast or slow aneurysm growth (frequency matched for baseline diameter) and subaneurysmal dilations. We measured plasma concentrations of thrombin-antithrombin (TAT) complex, platelet factor 4 (PF4), and D-dimer in 352 patients with either fast-growing AAAs (>2 mm/y), slow-growing AAAs (<2 mm/y), subaneurysmal aortic dilations, or nonaneurysmal aortas. Plasma D-dimer and TAT were significantly elevated in both AAA and subaneurysmal dilation patients compared with controls. Individuals with D-dimer levels ≥500 ng/mL had 3.09 times the odds of subaneurysms, 6.23 times the odds of slow-growing AAAs, and 7.19 times the odds of fast-growing AAAs than individuals with D-dimer level <500 ng/mL. However, no differences in D-dimer concentration were noted between fast- and slow-growing aneurysms. Plasma D-dimer and TAT were strong independent predictors of AAA growth rate with multivariate analysis revealing a 500-ng/mL increase in D-dimer or 1-µg/mL increase in TAT led to additional 0.21-mm and 0.24-mm changes in aortic diameter per year, respectively. Rising levels of plasma TAT, in addition to D-dimer, may predict disease progression and aneurysm growth in patients with AAA or subaneurysmal dilation.
腹主动脉瘤 (AAA) 与高发病率和死亡率相关,是血液失衡的既定原因。许多止血生物标志物与 AAA 相关;然而,止血生物标志物在 AAA 诊断和预后中的应用尚不清楚。本研究的目的是描述 D-二聚体和改变的止血标志物在一组大的 AAA 患者中的潜在预后价值,这些患者的 AAA 表现为快速或缓慢的动脉瘤生长(基于基线直径进行频率匹配)和亚瘤扩张。我们测量了 352 例快速生长的 AAA(>2 mm/y)、缓慢生长的 AAA(<2 mm/y)、亚瘤扩张或非瘤主动脉患者的血浆凝血酶-抗凝血酶(TAT)复合物、血小板因子 4(PF4)和 D-二聚体浓度。与对照组相比,AAA 和亚瘤扩张患者的血浆 D-二聚体和 TAT 均显著升高。D-二聚体水平≥500ng/mL 的个体发生亚瘤的几率是 D-二聚体水平<500ng/mL 的个体的 3.09 倍,发生缓慢生长的 AAA 的几率是<500ng/mL 的个体的 6.23 倍,发生快速生长的 AAA 的几率是<500ng/mL 的个体的 7.19 倍。然而,快速生长的动脉瘤和缓慢生长的动脉瘤之间的 D-二聚体浓度没有差异。血浆 D-二聚体和 TAT 是 AAA 生长速度的强独立预测因子,多变量分析显示 D-二聚体增加 500ng/mL 或 TAT 增加 1μg/mL,每年主动脉直径分别增加 0.21mm 和 0.24mm。血浆 TAT 水平升高,除了 D-二聚体之外,可能预测 AAA 或亚瘤扩张患者的疾病进展和动脉瘤生长。